Khorana risk score: Risk prediction of chemotherapy associated thrombosis
The Khorana risk score predicts the risk of venous thromboembolism (VTE) in cancer patients initiating chemotherapy. 

 
Research authors: Alok A. Khorana, Nicole M. Kuderer, Eva Culakova, Gary H. Lyman, Charles W. Francis
Details Formula Study characteristics Files & References
★★★★
Model author
Model ID
1068
Version
1.5
Revision date
2017-12-15
Specialty
MeSH terms
  • Venous Thromboembolism
  • Thrombosis
  • Chemotherapy
  • Model type
    Linear model (Calculation)
    Status
    public
    Rating
    Share
    Formula
    No Formula defined yet
    Condition Formula

    Additional information

    The study population comprised 4066 patients, split into 2701 patients in the derivation cohort and 1365 patients in the validation cohort. Overall, 88 patients (2.2%) developed VTE over a median follow up of 73 days, (range, 5-364 days). There were 65 reported venous thrombotic events (1.6%) and 27 embolic events (0.7%), including 4 patients with both. Seventy-five percent of VTE events occurred in the first 2 cycles. 

    Study Population

    Total population size: 2701
    Males: {{ model.numberOfMales }}
    Females: {{ model.numberOfFemales }}

    Categorical characteristics

    Name Subset / Group Nr. of patients
    Age Younger than 65y 1618
    65 y or older 1083
    Sex Male 882
    Female 1819
    Performance status, ECOG 0 to 1 2473
    2 to 4 228
    Primary site of cancer Breast 935
    Colorectal 297
    Lung 554
    Gynecologic 259
    Gastric and pancreatic 54
    Lymphoma 328
    Other sites 274
    Stage 1 to 3 1653
    4 997
    Unknown 51
    Comorbidities Cerebrovascular disease 54
    Moderate or severe renal disease 27
    Chronic pulmonary disease 217
    Surgery within past month 829
    Diabetes mellitus 312
    Baseline laboratory values Platelet count 350 x 10^9/L or more 604
    Hemoglobin level less than 100 g/L 178
    WBC count more than 11 x 10^9/L 344
    Bilirubin level more than 17.1 umol/L 103
    Albumin level less than 35 g/L 544
    Creatinine level more than 114.4 umol/L 89
    Drugs Erythropoiesis-stimulating agents reported up to cycle 2 764
    Prophylactic myeloid growth factors 566
    Antibiotics 131
    Corticosteroids 712
    Khorana risk score: Risk prediction of chemotherapy associated thrombosis
    V-1.5-1068.17.12.15
    Refer to Intended Use for instructions before use
    Evidencio B.V., Irenesingel 19, 7481 GJ, Haaksbergen, the Netherlands

    The Khorana risk score is:
    ...

    {{ resultSubheader }}

    {{ model.survival.PITTitle }}

    {{ model.survival.YNETitle }}

    Result
    Note
    Notes are only visible in the result download and will not be saved by Evidencio

    The Khorana risk score is:

    {{ resultSubheader }}
    {{ chart.title }}

    Outcome stratification

    Result interval {{ additionalResult.min }} to {{ additionalResult.max }}

    Conditional information

    Result interpretation

    Interpret the results with care, not all validations of the Khorana risk score showed it to be a valid tool for discriminating between patients at low and high risk of thrombosis. 

    {{ file.classification }}

    Calculations alone should never dictate patient care, and are no substitute for professional judgement. See our full disclaimer.

    Comments
    Rating
    Comment
    Please enter a comment of rating
    Comments are visible to anyone

    Model feedback

    No feedback yet 1 Comment {{ model.comments.length }} Comments
    Not rated | On {{ comment.created_at }} {{ comment.user.username }} a no longer registered author wrote:
    logo

    Please sign in to enable Evidencio print features

    In order to use the Evidencio print features, you need to be logged in.
    If you don't have an Evidencio Community Account you can create your free personal account at:

    https://www.evidencio.com/registration

    Printed results - Examples {{ new Date().toLocaleString() }}


    Evidencio Community Account Benefits


    With an Evidencio Community account you can:

    • Create and publish your own prediction models.
    • Share your prediction models with your colleagues, research group, organization or the world.
    • Review and provide feedback on models that have been shared with you.
    • Validate your models and validate models from other users.
    • Find models based on Title, Keyword, Author, Institute, or MeSH classification.
    • Use and save prediction models and their data.
    • Use patient specific protocols and guidelines based on sequential models and decision trees.
    • Stay up-to-date with new models in your field as they are published.
    • Create your own lists of favorite models and topics.
    A personal Evidencio account is free, with no strings attached! Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction models.

    Disclaimer: Calculations alone should never dictate patient care, and are no substitute for professional judgement.